leadf
logo-loader
viewBiocept Inc
(
NASDAQ:BIOC
)

Biocept expands uses for its Target Selector liquid biopsy tech, expands coronavirus testing

Biocept Inc (NASDAQ: BIOC) CEO Mike Nall tells Proactive the molecular diagnostics company, is expanding uses for its flagship liquid biopsy Target Selector technology which detects cancer biomarkers.

What's more, Nall says, is the California-based company is expanding its coronavirus molecular diagnostic test to its current client base, with a current capacity of 100 tests per day, with the ability to ramp its capacity to 400 tests per day.

Quick facts: Biocept Inc

Follow
NASDAQ:BIOC

Price: 3.9 USD

Market Cap: $57.42 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Biocept approved for expanded Medicare coverage for its Target Selector...

Biocept Inc (NASDAQ:BIOC) (NASDAQ:BIOC) (FRA:B003) CEO Mike Nall tells Proactive it has received a positive final Local Coverage Determination from the Centers for Medicare & Medicaid Services Molecular Diagnostics Program, which will expand Medicare coverage for use of Biocept’s Target...

on 07/27/2021

2 min read